Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

87.94 +0.64 (+0.74%)
Streaming Delayed Price Updated: 10:39 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
7 Stocks 'On Sale' This Holiday Season
This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have... 
Via Talk Markets
7 Stocks 'On Sale' This Holiday Season
The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In... 
Via Benzinga
Topics Stocks
Expert Ratings For Incyte
Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ: 
Via Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Expert Ratings For Incyte
Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Stocks Most Impacted by 7-10 Year Treasuries
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value. 
Via Talk Markets
Topics Stocks
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
From Incyte
Via Business Wire
Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript
INCY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will... 
Via Benzinga
Topics Economy
Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),... 
Via Benzinga
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
From Incyte
Via Business Wire
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
From Incyte
Via Business Wire
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
From Incyte
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays
It's much too early to count these companies out. 
Via The Motley Fool
Could This Be the Next Blockbuster Indication for Eli Lilly?
Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata. 
Via The Motley Fool
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Incyte Names New Member to Its Board of Directors
From Incyte
Via Business Wire
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license... 
Via Benzinga
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.